http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111419841-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 |
| filingDate | 2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111419841-B |
| titleOfInvention | Anti-candida albicans combined medicine |
| abstract | An anti-candida albicans combination drug belongs to the field of antifungal drugs and comprises dihydroartemisinin and fluconazole. Through the research of the prior art, dihydroartemisinin has almost no antifungal effect when being used alone, but the combined application of dihydroartemisinin and fluconazole is found in the research of the invention, so that the antibacterial activity of fluconazole on drug-resistant candida albicans can be enhanced, a synergistic antifungal effect is generated, the drug resistance of candida albicans on fluconazole is reversed by inducing the generation of intracellular active oxygen, and a direction is provided for the development of new antifungal medicines and the new old medicine application of traditional Chinese medicines. |
| priorityDate | 2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.